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Allograft  and  tumor rejection  have been  shown  to be mediated  by both  humoral 
(antibody)  and cellular mechanisms  (1, 2). However, the actual lymphocyte subpop- 
ulations  involved in the cell-mediated rejection phenomenon  remain to be identified. 
Cytolytic T  lymphocytes (CTL) have been considered as a  leading candidate  because 
they have been shown to be generated during graft rejection  (2), to be highly cytolytic 
for the relevant target cells in vitro (3), to inhibit tumor growth in vivo when admixed 
with  tumor  cells  (4),  and  to  accumulate  selectively  in  grafts  (5)  and  tumors  (6). 
Nevertheless, recent reports question the role of CTL in vivo because precursor T  cells 
of the  Lyt-2-  phenotype  and  not  Lyt-2  +  (cytolytic)  cells  were  shown  to  mediate 
murine  allograft  (7)  and  rat  syngeneic  tumor  rejection  (8).  With  the  possibility  of 
deriving and  maintaining  in continuous  culture clones of functionally  active T  cells, 
(9-12),  the  use  of such  cloned  effector  T  cells  should  provide  a  direct  means  of 
resolving these contradictory  observations. 
Previous  experiments  testing  several  allogeneic  and  syngeneic  CTL  clones  had 
failed to show a  protective effect against tumor grafts after intravenous  injection  (13, 
14),  results  that  might  be explained  by an  inadequate  homing  pattern  (15)  and/or 
limited survival of such clones in vivo (16). In vitro, CTL clones have been  found  to 
depend  on  addition  of exogenous  T  cell  growth  factor  (TCGF)  for  survival  and 
responsiveness to antigenic stimulation  (9-12). In view of recent evidence demonstrat- 
ing the existence of antigen-driven CTL clones able to proliferate autonomously upon 
stimulation  with  alloantigen  in  the  absence  of added  TCGF  (17), 1 several  autono- 
mously proliferating CTL clones were selected for the present studies. We demonstrate 
the  ability  of certain  Lyt-2  +  CTL  clones,  when  injected  intravenously,  to  induce 
aliogeneic  tumor cell  destruction  within  the  peritoneal  cavity of immunosuppressed 
histocompatible  mice. 
Materials  and Methods 
Using techniques described in detail elsewher@ CTL clones specific for H-2 K/D alloantigens 
were isolated from day-5 primary C57BL/6  (H-2  b) anti-P-815  (H-2  d)  mixed leukocyte-tumor 
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cell cultures. Individual blast cells were micromanipulated into microwells containing irradiated 
P-815 tumor cells,  irradiated  syngeneie spleen  cells,  and  a  source of TCGF. 1 The resultant 
clones were tested for antigen-induced proliferation  in the absence of added TCGF and for 
cytolytic activity on 51Cr-labeled  P-815 tumor cells. Four autonomously proliferating cytolytic 
clones were selected,  expanded in mass culture, and evaluated for the ability to induce tumor 
cell  destruction  i.p.  in  syngeneic,  sublethally  irradiated  (650  rad)  mice  after  intravenous 
injection (13, 14). Tumor cells were initially labeled with 13tI-IUdR (18) and then 2 ×  106 cells 
injected intraperitoneally.  Tumor cell  survival was monitored by whole-body counting tech- 
niques  (14,  18) because ~alI label released from dead tumor cells is eliminated without reuse. 
The clones were further studied  for specificity of cytolysis using several  5XCr-labeled tumor 
targets (3), antigen-induced production of lymphokines y-interferon (IFN-7) and macrophage- 
activating factor(s)  (MAF)  (19), and cell surface phenotype using monoclonal antibodies and 
flow cytofluorographic analysis (20). 
Results 
Fig.  1 shows  that  two  of the  four clones  tested  were  able  to  mediate  allogeneic 
tumor cell rejection after intravenous infusion, i.e., clones AL 15 (Fig.  1 A) and AO 37 
(Fig.  1 B). It should be noted that the two clones that were active in vivo were derived 
in  independent  experiments.  Clone  AL  15  cells  induced  a  rapid,  dose-dependent 
destruction  of labeled  tumor cells  in  the peritoneal  cavity.  20  million  cloned CTL 
injected intravenously resulted in the elimination by day 9 of >95% of the x31I-IUdR 
label initially injected (Fig. 1 A). This dose of cloned T  cells resulted in total protection 
of the mice, as assessed by survival 35 d  later, in contrast to 5 ×  106 cells that did not 
yield protection. The control group, which received 20 ×  106 normal syngeneic spleen 
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Fzo.  1.  Allogeneic tumor cell destruction induced by the intravenous injection of Lyt-2  + cytolytic 
T  cell  clones  directed  against  H-2  K/D  alloantigens.  The  elimination  of  lsaI-IUdR-labeled 
(DBA/2)  P-815  tumor  cells  injected  intraperitoneally  was  monitored  by  whole-body counting 
techniques (14,  18). Groups of 4-6 sublethally irradiated  (650  rad)  C57BL/6  mice were injected 
intraveI3ously (i.v.) with various C57BL/6 (H-2  b) anti-P-815 (H-2  d) CTL clones, followed immedi- 
ately by 2 ×  106 labeled P-815 intraperitoneally. A, (0) 20 X  10  s C57BL/6 normal spleen cells i.v.; 
(O)  1 ×  106 clone AL 15 i.v.; (A) 5 ×  106 clone AL 15 i.v.; (')  20 ×  10  s clone AL 15 i.v. B, (0) 20 
×  106 C57BL/6 normal spleen cells i.v.; (X) 20 ×  l0  s clone AL 33 i.v.; (A) 20 ×  106 clone AO 24 
i.v.; (f-q) 20 ×  I0  e clone AO 37 i.v. 1282  ENGERS  ET  AL.  BRIEF  DEFINITIVE  REPORT 
cells intravenously, retained 30-fold more radioactivity as measured on day 9, and all 
mice were dead with ascites by day 18 of experiment. CTL clone AO 37 gave similar 
results when tested in an independent experiment  (Fig.  1 B), whereas clone AO  24 
induced only a partial elimination of the labeled P-815 cells. Interestingly, CTL clone 
AL 33, which was isolated in an identical manner, failed to confer protection after 
injection of 20 ×  106 cells intravenously (Fig.  1 B). 
Table I summarizes several in vitro activities exhibited by the CTL clones described 
in Fig.  I. All clones were highly cytolytic when tested on 51Cr-labeled P-815  (H-2  a) 
cells, the original stimulating alloantigen, and gave no detectable lysis of syngeneic 
EL-4 (H-2  b) or of third-party BW5147  (H-2  k)  tumor target cells. All clones secreted 
considerable levels of the lymphokines IFN-y and MAF during the expansion phase 
in Costar 24-well plates. 
Fig. 2 depicts the cell surface phenotype of AL 15 and AO 37, the two clones that 
afforded protection, in addition to that of the nonprotective clone AL 33.  All CTL 
clones expressed Lyt-2 but the expression of Lyt- 1 was variable, as has been observed 
previously (11 ,12). 
Discussion 
Although individual T  cell clones specific for SRBC (21), y, influenza virus (22), or 
parasite antigens  (23)  have been shown  to function in  vivo, this  is  the  first report 
demonstrating the tumoricidal activity of alloreactive cloned Lyt-2  + cytolytic T  cells 
in vivo after intravenous injection. Two out of the four autonomously proliferating 
CTL clones tested induced tumor cell destruction at a site distant from their injection. 
These results are in contrast to previous attempts in which six CTL clones failed to 
afford protection (13,  14). 
Because the CTL clones analyzed in this study proliferate autonomously in vitro in 
response to stimulation with alloantigens, in the absence of an added source of TCGF, 
TABLE  I 
Characteristics of Murine  CTL Clones Tested for the Ability to Induce Tumor Rejection 
after Intravenous Injection 
Cytolytic activity  MAF 
(LU/106 cells)  IFN-y  pro-  Tumor 
Clone  Surface phenotype  produc-  rejec- 
injected  P-815  EL-4  BW5147  tion  due-  tion 
(H_2 d)  (H_2 b)  (H_2 k)  tion 
Experiment 1 
U  U 
AL 15  Thy-I +, Lyt-l-2  +  714  <0.3  <0.3  160  69  +++ 
AL 33  Thy-1 +, Lyt-l-2  +  333  <0.3  <0.3  160  61  - 
Experiment 2  AO 24  Thy-1 +, Lyt-l÷2  +  625  <0.3  <0.3  640  314  + 
AO 37  Thy-1 ÷, Lty-l+2  +  330  <0.3  <0.3  1,280  897  +++ 
Murine T  cell clones were derived by micromanipulation  techniques starting  from  a  day  5  C57BL/6 
(H-2~ anti-P-815 (H-2  a) allogeneic mixed leukocyte-tumor culture as described elsewhere.1 Cytolytic clones 
that proliferated autonomously when cultured with irradiated  P-815 tumor cells plus irradiated T  cell- 
depleted syngeneic spleen cells in the absence of added TCGF were expanded in Costar 24-well plates and 
tested for ability to induce the rejection of 131I-IUdR-labeled P-815 tumor cells after intravenous injection 
(14,  18) (Fig.  1), cell surface phenotype (20), (Fig. 2), cytolytic activity on 51Cr-labeled tumor cells expressed 
as lytic units per  106 cloned T  cells  (3),  and  production of the lymphokines y-interferon (IFN-y)  and 
macrophage-activation factor (MAF) expressed in units per ml relative to a standard preparation (19). ENGERS  El" AL.  BRIEF DEFINITIVE REPORT 
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F1o. 2.  Cell  surface phenotype of  CTL clones. 1 million cells of  clone AL 15, clone AL 33, or clone 
AO 37 were incubated with monoclonal rat antibodies against Lyt-2 (A, D, G) or Lyt-I (B, E, H) 
followed by FITC-conjugated rabbit anti-rat Ig and analyzed on an FACS II flow cytometer (20). 
Control samples (C, F, I) were stained with the fluorescent anti-Ig reagent alone. Each histogram 
represents 10,000 viable cells gated according to forward light scatter. (a.u, arbitrary units). 
it  is  tempting  to speculate  that  this  selected  subpopulation  of Lyt-2  +  CTL effector 
cells is especially suited to function in vivo after intravenous administration. It should, 
however, be noted that on a  per cell basis, the protective CTL clones were 5-20-fold 
less  efficient  at  inducing  tumor  cell  rejection  in  vivo  than  were  equally  cytolytic 
Lyt-2  +  cell  populations  recovered  from  day  5  mixed  leukocyte  cultures  (13,  14). 
Preliminary results using lalI-IUdR-labeled CTL clones demonstrate that up to 70% 
of the injected cells recovered are trapped in the lungs after intravenous injection (13, 
unpublished observations). This may be one reason for the lower efficiency of cloned 
CTL  cells  vs.  the  day  5  mixed  leukocyte culture  effector  cells.  In  addition,  these 
observations may explain  the positive results obtained in a  previous report, whereby 
intravenous injection of an influenza-specific CTL clone protected mice from a  nasal 
infection with virus (22). 
The mechanism by which the injected effector cells accomplish the actual destruc- 
tion of the tumor cells in vivo in this model system remains to be elucidated. Although 
it  appears  likely to be via direct  cytolytic activity,  a  participation  of radioresistant 1284  ENGERS  ET AL.  BRIEF  DEFINITIVE REPORT 
host  cells,  e.g.,  activated  macrophages,  cannot  be  ruled  out.  In  addition,  all  CTL 
clones tested secreted considerable levels oflFN-y in vitro. Experiments are in progress 
to investigate the production of IFN-y in vivo in this model system. It also remains to 
be established  whether differences in homing patterns  between  various T  cell clones 
exist,  and,  if so,  what  role  these  differences  might  play  in  the  functional  activities 
displayed by these clones. 
Summary 
The in vivo activity of murine Lyt-2  + cytolytic T  lymphocyte clones was assessed 
in a  tumor allograft  model system.  Mice that  had  been sublethally  irradiated  16  h 
previously were injected intraperitoneally  with lalI-IUdR-labeled tumor cells. Simul- 
taneously, various doses of four cytolytic T  cell clones were injected intravenously and 
the mice monitored  for tumor cell elimination  by whole-body counting techniques. 
These  four  clones  had  been  selected  on  the  basis  of their  ability  to  proliferate  in 
response to alloantigens in the absence of added T  cell growth factor(s). With two of 
the  four clones tested,  rapid  elimination  of tumor cells within  the peritoneal  cavity 
was observed, as early as 48 h  after intravenous injection of the cloned T  cells. 
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